Loading…
Protecting Access to Diabetes Supplies Act of 2015
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
49pct
13d open
vs 6,526 other HR bills in the 114th — cohort avg 56d
Protecting Access to Diabetes Supplies Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to revise the special competitive acquisition program rule applied to diabetic testing strips to require the volume for such types of products to be determined through the use of multiple sources of data that measure consumption and utilization of such strips among individuals in the United States. Directs the Secretary of Health and Human Services to reject any bid submitted by an entity under the competitive acquisition program that does not demonstrate that it can furnish the types of strips included in its bid. Requires an entity to furnish to an individual the brand of strips compatible with the individual's home blood glucose monitor. Prohibits an entity from attempting to influence or incentivize an individual to switch the brand of glucose monitor or testing strips selected. Prohibits an entity from communicating directly to such an individual until it has given the individual verbally standardized information about the individual's rights with respect to the entity. Directs the Secretary to establish a process under which an individual furnished with diabetic testing strips under a competitive acquisition program may reject them by notifying the supplier and the Secretary. Permits the individual to obtain different strips from another supplier and have a new claim processed.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (8)
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congress.gov source codes: H11100, H11100-A
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2017 · second_quarter · Pharmacy
H.R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015.
Client expense: $130,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · second_quarter · Medicare/Medicaid
H. R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015.
Client expense: $130,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · second_quarter · Health Issues
H.R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015. H.R. xxxx - Regulatory framework for in-vitro clinical tests (unnamed discussion draft, and Diagnostic Accuracy and Innovation Act).
Client expense: $130,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · first_quarter · Medicare/Medicaid
H. R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015.
Client expense: $145,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Health Issues
H.R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015. H.R. xxxx - Regulatory framework for in-vitro clinical tests (unnamed discussion draft, and Diagnostic Accuracy and Innovation Act).
Client expense: $145,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Pharmacy
H.R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015.
Client expense: $145,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to womens health issues. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to age restrictions on access to particular drugs. Monitor activities related to the implementation of the Drug Quality and Security Act (2013). Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to companion labeling. Monitor legislative and administrative action related to FDA monograph reform and user fees. S. 1878, Advancing Hope Act of 2015. S. 1890, Defend Trade Secrets Act of 2016. S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act. H.R. 6, 21st Century Cures Act. H.R. 34, 21st Century Cures Act. H.R. 771, Protecting Access to Diabetes Supplies Act of 2015. H.R. 1537, Advancing Hope Act of 2015. H.R. 2459, Delivering Antimicrobial Transparency in Animals Act of 2015. H.R. 3299, Strengthening Public Health Emergency Response Act of 2015. H.R. 3326, Defend Trade Secrets Act of 2016. H.R. 3920, E-Free Act.
Client expense: $1,880,000 · Firm income: Not reported
2016 · third_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to womens health issues. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to age restrictions on access to particular drugs. Monitor activities related to the implementation of the Drug Quality and Security Act (2013). Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to companion labeling. S. 1878, Advancing Hope Act of 2015. S. 1890, Defend Trade Secrets Act of 2016. S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act. H.R. 6, 21st Century Cures Act. H.R. 771, Protecting Access to Diabetes Supplies Act of 2015. H.R. 1537, Advancing Hope Act of 2015. H.R. 2459, Delivering Antimicrobial Transparency in Animals Act of 2015. H.R. 3299, Strengthening Public Health Emergency Response Act of 2015. H.R. 3326, Defend Trade Secrets Act of 2016. H.R. 3920, E-Free Act.
Client expense: $2,260,000 · Firm income: Not reported
2016 · first_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to womens health issues. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to age restrictions on access to particular drugs. Monitor activities related to the implementation of the Drug Quality and Security Act (2013). Monitor legislative and administrative action related to dietary supplements. S. 1878, Advancing Hope Act of 2015. S. 1890, Defend Trade Secrets Act of 2016. S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act. H.R. 6, 21st Century Cures Act. H.R. 771, Protecting Access to Diabetes Supplies Act of 2015. H.R. 1537, Advancing Hope Act of 2015. H.R. 2459, Delivering Antimicrobial Transparency in Animals Act of 2015. H.R. 3326, Defend Trade Secrets Act of 2016. H.R. 3920, E-Free Act.
Client expense: $2,130,000 · Firm income: Not reported
2016 · fourth_quarter · Medicare/Medicaid
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies; H.R.1726 - Access to Quality Diabetes Education Act of 2015
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
H.R.6-21st Century Cures Act; Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; H.R. 771-Protecting Access to Diabetes Supplies Act of 2015; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies.
Client expense: $110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · fourth_quarter · Pharmacy
H.R. 771 - Protecting Access to Diabetic Testing Supplies Act of 2015. Yet to be introduced Senate proposal on Medicare Competitive Bidding related to diabetes testing supplies.
Client expense: $110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · fourth_quarter · Medicare/Medicaid
HR 771: Protecting Access to Diabetic Testing Supplies Act of 2015. S.4 - Protecting Access to Diabetes Supplies Act of 2016. Legislation affecting Medicare payments for laboratory services. WHO PQ Process for Diagnostics. Develop streamlined process to get QW modifier added to tests that are granted CLIA-waived status by the FDA.
Client expense: $110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · fourth_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to womens health issues. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to age restrictions on access to particular drugs. Monitor activities related to the implementation of the Drug Quality and Security Act (2013). Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to companion labeling. Monitor legislative and administrative action related to FDA monograph reform and user fees. S. 1878, Advancing Hope Act of 2015. S. 1890, Defend Trade Secrets Act of 2016. S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act. H.R. 6, 21st Century Cures Act. H.R. 34, 21st Century Cures Act. H.R. 771, Protecting Access to Diabetes Supplies Act of 2015. H.R. 1537, Advancing Hope Act of 2015. H.R. 2459, Delivering Antimicrobial Transparency in Animals Act of 2015. H.R. 3299, Strengthening Public Health Emergency Response Act of 2015. H.R. 3326, Defend Trade Secrets Act of 2016. H.R. 3920, E-Free Act.
Client expense: $1,870,000 · Firm income: Not reported
2016 · fourth_quarter · Health Issues
S.804/HR.1427 MEDICARE CGM ACCESS ACT OF 2015, S.586/HR1192 NDCCA, S.1345/HR 1726 ACCESS TO QUALITY DIABETES EDUCATION ACT, S.1131/HR2102 MEDICARE NDPP, HR 771 PROTECTING ACCESS TO DIABETES SUPPLIES ACT, HR 1686 MEDICARE PREVENTION NUTRITION EDUCATION, MEDICARE COMPETITIVE BIDDING PROGRAM,
Client expense: Not reported · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · third_quarter · Medicare/Medicaid
HR 771: Protecting Access to Diabetic Testing Supplies Act of 2015. Yet to be introduced proposal on Medicare Competitive Bidding related to diabetes testing supplies. Legislation affecting Medicare payments for laboratory services.
Client expense: $90,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · third_quarter · Health Issues
H.R.6-21st Century Cures Act; Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; H.R. 771-Protecting Access to Diabetes Supplies Act of 2015; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies.
Client expense: $90,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · third_quarter · Pharmacy
H.R. 771 - Protecting Access to Diabetic Testing Supplies Act of 2015. Yet to be introduced Senate proposal on Medicare Competitive Bidding related to diabetes testing supplies.
Client expense: $90,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · third_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to womens health issues. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to age restrictions on access to particular drugs. Monitor activities related to the implementation of the Drug Quality and Security Act (2013). Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to companion labeling. S. 1878, Advancing Hope Act of 2015. S. 1890, Defend Trade Secrets Act of 2016. S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act. H.R. 6, 21st Century Cures Act. H.R. 771, Protecting Access to Diabetes Supplies Act of 2015. H.R. 1537, Advancing Hope Act of 2015. H.R. 2459, Delivering Antimicrobial Transparency in Animals Act of 2015. H.R. 3299, Strengthening Public Health Emergency Response Act of 2015. H.R. 3326, Defend Trade Secrets Act of 2016. H.R. 3920, E-Free Act.
Client expense: $2,250,000 · Firm income: Not reported
2016 · third_quarter · Medicare/Medicaid
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies; H.R.1726 - Access to Quality Diabetes Education Act of 2015
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
competitive bidding for diabetes supplies H.R. 771, Protecting Access to Diabetes Supplies Act of 2015
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
S.804/HR.1427 MEDICARE CGM ACCESS ACT OF 2015, S.586/HR1192 NDCCA, S.1345/HR 1726 ACCESS TO QUALITY DIABETES EDUCATION ACT, S.1131/HR2102 MEDICARE NDPP, HR 771 PROTECTING ACCESS TO DIABETES SUPPLIES ACT, HR 1686 MEDICARE PREVENTION NUTRITION EDUCATION, MEDICARE COMPETITIVE BIDDING PROGRAM, Docket No. FDA-2016-N-0400 FDA LANCET DEVICES GUIDANCE DOCKET, Docket No. FDA-2016-N-0001 FDA DIABETES DEXCOM G5 LABELING CHANGE
Client expense: Not reported · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · second_quarter · Health Issues
S. 1622 FDA Device Accountability Act of 2015. H.R. 5009 Ensuring Patient Access to Critical Breakthrough Products Act of 2016. H.R. 771 Protecting Access to Diabetes Supplies Act of 2015. Proposals regarding payments across healthcare sites of service. Proposals to provide Diagnostic Regulatory Reform.
Client expense: $360,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2016 · second_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to womens health issues. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to age restrictions on access to particular drugs. Monitor activities related to the implementation of the Drug Quality and Security Act (2013). Monitor legislative and administrative action related to dietary supplements. S. 1878, Advancing Hope Act of 2015. S. 1890, Defend Trade Secrets Act of 2016. S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act. H.R. 6, 21st Century Cures Act. H.R. 771, Protecting Access to Diabetes Supplies Act of 2015. H.R. 1537, Advancing Hope Act of 2015. H.R. 2459, Delivering Antimicrobial Transparency in Animals Act of 2015. H.R. 3299, Strengthening Public Health Emergency Response Act of 2015. H.R. 3326, Defend Trade Secrets Act of 2016. H.R. 3920, E-Free Act.
Client expense: $1,550,000 · Firm income: Not reported
2016 · second_quarter · Health Issues
H.R.160-Protect Medical Innovation Act of 2015. S.149-Medical Device Access and Innovation Protection Act. HR.6-21st Century Cures Act. Yet to be introduced House proposal to have the FDA regulate laboratory developed tests. Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests. H.R. 771-Protecting Access to Diabetes Supplies Act of 2015. Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies. HCR Competitive Bidding. H.R.6-21st Century Cures Act; Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; H.R. 771-Protecting Access to Diabetes Supplies Act of 2015; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies. Monitored Congressional actions on HR 6, 21st Century Cures Act.
Client expense: $160,000 · Firm income: Not reported
2016 · second_quarter · Medicare/Medicaid
competitive bidding for diabetes supplies H.R. 771, Protecting Access to Diabetes Supplies Act of 2015
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
S.804/HR.1427 MEDICARE CGM ACCESS ACT OF 2015, S.586/HR1192 NDCCA, S.1345/HR 1726 ACCESS TO QUALITY DIABETES EDUCATION ACT, S.1131/HR2102 MEDICARE NDPP, HR 771 PROTECTING ACCESS TO DIABETES SUPPLIES ACT, HR 1686 MEDICARE PREVENTION NUTRITION EDUCATION, MEDICARE COMPETITIVE BIDDING PROGRAM, Docket No. FDA-2016-N-0400 FDA LANCET DEVICES GUIDANCE DOCKET, Docket No. FDA-2016-N-0001 FDA DIABETES DEXCOM G5 LABELING CHANGE
Client expense: Not reported · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · second_quarter · Health Issues
S.804/HR.1427 - MEDICARE CGM ACCESS ACT OF 2015, S.586/HR.1192 - NDCCA, S.1345/HR 1726 ACCESS TO DIABETES QUALITY EDUCATION ACT, S.1131/HR.2102 MEDICARE NDPP, HR.771 PROTECTING ACCESS TO DIABETES SUPPLIES ACT, HR 1686 MEDICARE PREVENTION NUTRITION EDUCATION, SPECIAL DIABETES FUNDING PROGRAM, CMS COMPETITIVE BIDDING PROGRAMS FOR DIABETES SUPPLIES, RESTRICTION OF ACCESS TO DIABETES TREATMENTS BY INSURANCE PROVIDERS
Client expense: Not reported · Firm income: Not reported
2016 · second_quarter · Insurance
S.804/HR.1427 - MEDICARE CGM ACCESS ACT OF 2015, S.586/HR.1192 - NDCCA, S.1345/HR 1726 ACCESS TO DIABETES QUALITY EDUCATION ACT, S.1131/HR.2102 MEDICARE NDPP, HR.771 PROTECTING ACCESS TO DIABETES SUPPLIES ACT, HR 1686 MEDICARE PREVENTION NUTRITION EDUCATION, SPECIAL DIABETES FUNDING PROGRAM, CMS COMPETITIVE BIDDING PROGRAMS FOR DIABETES SUPPLIES, RESTRICTION OF ACCESS TO DIABETES TREATMENTS BY INSURANCE PROVIDERS
Client expense: Not reported · Firm income: Not reported
2016 · second_quarter · Medicare/Medicaid
S.804/HR.1427 - MEDICARE CGM ACCESS ACT OF 2015, S.586/HR.1192 - NDCCA, S.1345/HR 1726 ACCESS TO DIABETES QUALITY EDUCATION ACT, S.1131/HR.2102 MEDICARE NDPP, HR.771 PROTECTING ACCESS TO DIABETES SUPPLIES ACT, HR 1686 MEDICARE PREVENTION NUTRITION EDUCATION, SPECIAL DIABETES FUNDING PROGRAM, CMS COMPETITIVE BIDDING PROGRAMS FOR DIABETES SUPPLIES, RESTRICTION OF ACCESS TO DIABETES TREATMENTS BY INSURANCE PROVIDERS
Client expense: Not reported · Firm income: Not reported
2016 · second_quarter · Pharmacy
S.804/HR.1427 - MEDICARE CGM ACCESS ACT OF 2015, S.586/HR.1192 - NDCCA, S.1345/HR 1726 ACCESS TO DIABETES QUALITY EDUCATION ACT, S.1131/HR.2102 MEDICARE NDPP, HR.771 PROTECTING ACCESS TO DIABETES SUPPLIES ACT, HR 1686 MEDICARE PREVENTION NUTRITION EDUCATION, SPECIAL DIABETES FUNDING PROGRAM, CMS COMPETITIVE BIDDING PROGRAMS FOR DIABETES SUPPLIES, RESTRICTION OF ACCESS TO DIABETES TREATMENTS BY INSURANCE PROVIDERS
Client expense: Not reported · Firm income: Not reported
2016 · second_quarter · Budget/Appropriations
S.804/HR.1427 - MEDICARE CGM ACCESS ACT OF 2015, S.586/HR.1192 - NDCCA, S.1345/HR 1726 ACCESS TO DIABETES QUALITY EDUCATION ACT, S.1131/HR.2102 MEDICARE NDPP, HR.771 PROTECTING ACCESS TO DIABETES SUPPLIES ACT, HR 1686 MEDICARE PREVENTION NUTRITION EDUCATION, SPECIAL DIABETES FUNDING PROGRAM, CMS COMPETITIVE BIDDING PROGRAMS FOR DIABETES SUPPLIES, RESTRICTION OF ACCESS TO DIABETES TREATMENTS BY INSURANCE PROVIDERS
Client expense: Not reported · Firm income: Not reported
2016 · first_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to womens health issues. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to age restrictions on access to particular drugs. Monitor activities related to the implementation of the Drug Quality and Security Act (2013). Monitor legislative and administrative action related to dietary supplements. S. 1878, Advancing Hope Act of 2015. S. 1890, Defend Trade Secrets Act of 2016. S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act. H.R. 6, 21st Century Cures Act. H.R. 771, Protecting Access to Diabetes Supplies Act of 2015. H.R. 1537, Advancing Hope Act of 2015. H.R. 2459, Delivering Antimicrobial Transparency in Animals Act of 2015. H.R. 3326, Defend Trade Secrets Act of 2016. H.R. 3920, E-Free Act.
Client expense: $2,080,000 · Firm income: Not reported
2016 · first_quarter · Health Issues
S. 1622 FDA Device Accountability Act of 2015. H.R. 6 - The 21st Century CURES Act, Sec. 2228. H.R. 771 Protecting Access to Diabetes Supplies Act of 2015. Proposals regarding HHS proposed rule to require informed consent for de-identified clinical specimens. Proposals regarding payments across healthcare sites of service. Proposals to provide Diagnostic Regulatory Reform.
Client expense: $440,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
2016 · first_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to womens health issues. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to age restrictions on access to particular drugs. Monitor activities related to the implementation of the Drug Quality and Security Act (2013). Monitor legislative and administrative action related to dietary supplements. S. 1878, Advancing Hope Act of 2015. S. 1890, Defend Trade Secrets Act of 2016. S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act. H.R. 6, 21st Century Cures Act. H.R. 771, Protecting Access to Diabetes Supplies Act of 2015. H.R. 1537, Advancing Hope Act of 2015. H.R. 2459, Delivering Antimicrobial Transparency in Animals Act of 2015. H.R. 3326, Defend Trade Secrets Act of 2016. H.R. 3920, E-Free Act.
Client expense: $2,090,000 · Firm income: Not reported
2016 · first_quarter · Medicare/Medicaid
Medicare competitive bidding program for diabetes testing supplies (for DACC, of which Roche is a member [1/3 share]). Medicare payment for point of care laboratory testing (for POCTA of which Roche is a member [1/5 share]). Policies related to diagnostic laboratory testing, H.R. 771 "Protecting Access to Diabetic Supplies"; S. 1101 "Medical Electronic Data Technology Enhancement for Consumers Health Act"; H.R. 6 "21st Century Cures Act";
Client expense: $160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015 Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies HPV NCCI Language Competitive bidding HR 771
Client expense: $160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Medicare/Medicaid
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; S. 1101 Medical Electronic Data Technology Enhancement for consumers Health Act; H.R. 6 "21st Century Cures Act".
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
HR 771, Protecting Access to Diabetes Supplies Act of 2015
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES
2015 · fourth_quarter · Health Issues
H.R. 6 - The 21st Century CURES Act, Sec. 2228. H.R. 771 Protecting Access to Diabetes Supplies Act of 2015. Proposals regarding payments across healthcare sites of service. Proposals to provide Diagnostic Regulatory Reform.
Client expense: $1,040,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2015 · fourth_quarter · Medicare/Medicaid
H.R. 2029 Consolidated Appropriations Act 2016, Sec. 503. H.R. 771 Protecting Access to Diabetes Supplies Act of 2015 Proposals to reform the Medicare new technology add-on payment provision for inpatient services. Proposed Hospital Inpatient Prospective Payment System Rule.
Client expense: $1,040,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2015 · fourth_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to womens health issues. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to age restrictions on access to particular drugs. Monitor activities related to the implementation of the Drug Quality and Security Act (2013). Monitor legislative and administrative action related to dietary supplements. H.R. 6, 21st Century Cures Act. H.R. 771, Protecting Access to Diabetes Supplies Act of 2015. H.R. 1537, Advancing Hope Act of 2015. H.R. 2459, Delivering Antimicrobial Transparency in Animals Act of 2015.
Client expense: $2,060,000 · Firm income: Not reported
2015 · fourth_quarter · Health Issues
H.R.160-Protect Medical Innovation Act of 2015 S.149-Medical Device Access and Innovation Protection Act H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015 Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies
Client expense: $135,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
H.R. 6 - The 21st Century CURES Act, Sec. 2228. H.R. 771 Protecting Access to Diabetes Supplies Act of 2015. Proposals regarding payments across healthcare sites of service. Proposals to provide Diagnostic Regulatory Reform.
Client expense: $840,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
| Democratic |
| IL |
| Brett Guthrie | Republican | KY |
| David Young | Republican | IA |
| Ed Whitfield | Republican | KY |
| Erik Paulsen | Republican | MN |
| Gene Green | Democratic | TX |
| Gus M. Bilirakis | Republican | FL |
| Hakeem S. Jeffries | Democratic | NY |
| Jackie Walorski | Republican | IN |
| John Katko | Republican | NY |
| Joseph J. Heck | Republican | NV |
| Kevin Yoder | Republican | KS |
| Kristi L. Noem | Republican | SD |
| Larry Bucshon | Republican | IN |
| Matt Cartwright | Democratic | PA |
| Mike Pompeo | Republican | KS |
| Pete Olson | Republican | TX |
| Peter J. Roskam | Republican | IL |
| Reid J. Ribble | Republican | WI |
| Renee L. Ellmers | Republican | NC |
| Robert J. Dold | Republican | IL |
| Rodney Davis | Republican | IL |
| Sanford D. Bishop, Jr. | Democratic | GA |
| Scott H. Peters | Democratic | CA |
| Scott R. Tipton | Republican | CO |
| Susan W. Brooks | Republican | IN |
| Tom Reed | Republican | NY |
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Trade Representative (USTR), White House Office